Products with Anti-osteoporosis bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1070 | 20(S)-Ginsenoside Rh2 |
| Ginsenoside Rh2 has memory-enhancing ,anti-osteoporosis, antitumor, antidiabetic, antiallergic, and anti-inflammatory effects, it potently protects ischemia-reperfusion brain injury, also inhibits prostaglandin-E_2 synthesis in lipopolysaccharide-stimulated RAW264.7 cells. It can inhibit the tendency of apoptosis, and reverse the impaired β-cell growth potential by modulating Akt/Foxo1/PDX-1 signaling pathway and regulating cell cycle proteins; it suppresses RANKL-induced osteoclast differentiation in vitro and in vivo through the regulation of c-Fos and NFATc1 expressions, not excluding the involvement of NF-κB and ERK. | |
| BCN1159 | Actein |
| 1. Actein has a stimulatory effect on osteoblastic bone formation or has potential activity against osteoporosis, it also can prevent oxidative damage to osteoblasts in osteoporotic patients. 2. Actein's ability to pathways involved in lipid disorders and carcinogenesis may make it a new agent for preventing and treating these major disorders. (1) Actein has been shown to inhibit the proliferation of human breast cancer cells, by altering the activity of the ER IP3 receptor and Na,K-ATPase, inducing calcium release and modulating the NF-κB and MEK pathways. (2) Actein reduces free fatty acid and cholesterol content in the liver by 0.6-fold at 24 h and inhibites the growth of human HepG2 liver cancer cells. | |
| BCN1222 | Aurantio-obtusin |
| Aurantio-obtusin possesses anti-allergic, vasorelaxation, hypotensive and hypolipidemic effects, it is a promising osteoanabolic compound with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases. Aurantio-obtusin can inhibit allergic responses in IgE-mediated mast cells and anaphylactic models, it suppresses degranulation, histamine production, and reactive oxygen species generation and inhibits the production and mRNA expression of tumor necrosis factor-α and interleukin-4, and also suppresses the prostaglandin E2 production and expression of cyclooxygenase 2. | |
| BCN1256 | Asperosaponin VI |
| Asperosaponin VI has antioxidant activity, it shows protective effect against hypoxia-induced cardiomyocytes apoptosis probably by activating the PI3K/Akt and CREB pathways, it also plays protective roles on acute myocardial infarction in rats. Asperosaponin VI may induce osteoblast maturation and differentiation, and then increase bone formation via increasing BMP-2 synthesis, and activating p38 and ERK1/2. | |
| BCN2163 | Veraguensin |
| 1. Veraguensin shows activity against trypomastigote T. cruzi. 2. Veraguensin and galgravin can inhibit bone resorption and may offer novel compounds for the development of drugs to treat bone-destructive diseases such as osteoporosis. 3. Veraguensin shows high antileishmanial activity. | |
